Experimental procedure aims to shrink untreatable childhood tumors
NCT ID NCT07136571
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a procedure called transarterial embolization in children aged 2-18 with incurable soft tissue sarcomas. The goal was to block blood flow to tumors using tiny particles, potentially slowing growth or easing symptoms. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bland particles (Embozene Color-Advanced Microspheres)
What this could lead to
If successful, this approach could offer a palliative option to shrink tumors and improve quality of life for children with incurable sarcomas.
What could go wrong
The trial was withdrawn before enrolling any participants, so no data exists. The approach is experimental and only targets certain tumors; benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.